CD274 and neoplasm: However, many other immune-related cardiac adverse events have been found in the clinical, such as myocarditis, heart failure, arrhythmia, myocardial hypertrophy, etc. Reporting cardiac adverse events during the treatment of tumor by anti-PD-1and PD-L1 drugs, providing a complete event profile and event spectrum, and to explore the safety of anti-PD-1and PD-L1 drugs will be considered essential.